Edward Anhoa Pham

US Patent:

20110288023, Nov 24, 2011

Filed:

Dec 6, 2010

Appl. No.:

12/961378

Inventors:

Daniel T. Kamei - Monterey Park CA, US
Bert J. Lao - Los Angeles CA, US
Wen-Lin P. Tsai - Oceanside CA, US
Foad Mashayekhi - Los Angeles CA, US
Edward A. Pham - Midway City CA, US
Anne B. Mason - Charlotte VT, US

Assignee:

The Regents of the University of California Office of Technology Transfer - Oakland CA
Office of Technology Transfer, University of Vermont - Burlington VT

International Classification:

A61K 38/40
A61P 35/00
C07K 14/79

US Classification:

514 153, 530395

Abstract:

The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments, the modified Tf molecule has a mutation which decreases the release of bound iron from a Tf complex. The complex can also contain, for instance, a carbonate, oxalate, or other anion to stabilize the Tf iron complex.

US Patent:

20090181048, Jul 16, 2009

Filed:

Jun 6, 2008

Appl. No.:

12/134922

Inventors:

Daniel T. Kamei - Monterey Park CA, US
Bert J. Lao - Los Angeles CA, US
Wen-Lin P. Tsai - Carlsbad CA, US
Foad Mashayekhi - Los Angeles CA, US
Edward A. Pham - Midway City CA, US
Anne B. Mason - Charlotte VT, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/05
C07K 14/79
C12N 9/96

US Classification:

42419711, 530394, 435188

Abstract:

The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making, as well as screening for, Tf conjugates with increased cellular association or cellular internalization. The present invention also provides Tf conjugates with increased cellular association and internalization for delivering nucleic acids to cancer cells.

US Patent:

20220347263, Nov 3, 2022

Filed:

Jun 9, 2020

Appl. No.:

17/617267

Inventors:

- Stanford CA, US
Edward A. Pham - Palo Alto CA, US
Anming Xiong - Redwood City CA, US

International Classification:

A61K 38/17
A61K 38/21
A61P 31/20

Abstract:

Methods and compositions are provided for reducing virus titer and eliminating virus-infected cells from an individual.

US Patent:

20220243198, Aug 4, 2022

Filed:

Apr 8, 2022

Appl. No.:

17/716497

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/11
A61P 31/16

Abstract:

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

US Patent:

20230072073, Mar 9, 2023

Filed:

Aug 1, 2022

Appl. No.:

17/878433

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/113
A61P 31/16
A61K 45/06

Abstract:

Methods of inhibiting a respiratory virus, (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods.

US Patent:

20210052553, Feb 25, 2021

Filed:

May 7, 2020

Appl. No.:

16/869312

Inventors:

- Palo Alto CA, US
Edward A. Pham - Shaker Heights OH, US

International Classification:

A61K 31/4184
A61K 31/4706
A61K 45/06
C07D 235/14
C07D 215/46
A61P 1/16
A61P 29/00
A61P 35/00

Abstract:

Disclosed herein are methods for use of clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory conditions. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.

US Patent:

20200239880, Jul 30, 2020

Filed:

Feb 14, 2020

Appl. No.:

16/792103

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/11
A61P 31/16

Abstract:

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

US Patent:

20180200228, Jul 19, 2018

Filed:

Jun 30, 2016

Appl. No.:

15/738827

Inventors:

- Palo Alto CA, US
Edward A. PHAM - Shaker Heights OH, US

International Classification:

A61K 31/4184
A61K 31/4706
A61K 45/06
A61P 29/00
A61P 35/00
A61P 1/16

Abstract:

Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory′ conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.